Danaher Co. (NYSE:DHR) Shares Bought by Patton Albertson Miller Group LLC

Patton Albertson Miller Group LLC lifted its position in shares of Danaher Co. (NYSE:DHR) by 3.6% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 42,258 shares of the conglomerate’s stock after purchasing an additional 1,461 shares during the period. Danaher comprises about 1.3% of Patton Albertson Miller Group LLC’s holdings, making the stock its 21st largest position. Patton Albertson Miller Group LLC’s holdings in Danaher were worth $9,700,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in DHR. Coronation Fund Managers Ltd. boosted its stake in shares of Danaher by 29.9% during the second quarter. Coronation Fund Managers Ltd. now owns 6,389 shares of the conglomerate’s stock worth $1,596,000 after buying an additional 1,470 shares during the period. Peloton Wealth Strategists lifted its position in Danaher by 1.3% during the 2nd quarter. Peloton Wealth Strategists now owns 5,764 shares of the conglomerate’s stock worth $1,440,000 after acquiring an additional 75 shares during the period. Oliver Lagore Vanvalin Investment Group increased its holdings in shares of Danaher by 12.3% in the second quarter. Oliver Lagore Vanvalin Investment Group now owns 4,098 shares of the conglomerate’s stock valued at $1,024,000 after purchasing an additional 448 shares during the period. Goodman Advisory Group LLC purchased a new stake in shares of Danaher during the second quarter worth approximately $209,000. Finally, Texas Capital Bank Wealth Management Services Inc lifted its holdings in shares of Danaher by 2.0% during the second quarter. Texas Capital Bank Wealth Management Services Inc now owns 32,138 shares of the conglomerate’s stock worth $8,030,000 after purchasing an additional 628 shares during the period. 79.05% of the stock is owned by hedge funds and other institutional investors.

Danaher Trading Up 0.1 %

Shares of DHR stock opened at $245.95 on Friday. The company has a market capitalization of $177.65 billion, a price-to-earnings ratio of 46.94, a PEG ratio of 4.43 and a beta of 0.83. The company has a current ratio of 1.37, a quick ratio of 1.01 and a debt-to-equity ratio of 0.32. The firm has a 50-day moving average price of $235.33 and a 200 day moving average price of $253.45. Danaher Co. has a twelve month low of $225.42 and a twelve month high of $281.70.

Danaher Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Friday, December 27th will be paid a dividend of $0.27 per share. This represents a $1.08 annualized dividend and a dividend yield of 0.44%. The ex-dividend date is Friday, December 27th. Danaher’s payout ratio is 20.61%.

Analyst Upgrades and Downgrades

DHR has been the subject of a number of analyst reports. Guggenheim assumed coverage on shares of Danaher in a research report on Thursday, December 19th. They set a “buy” rating and a $275.00 price objective for the company. TD Cowen raised their price objective on shares of Danaher from $310.00 to $315.00 and gave the company a “buy” rating in a research report on Wednesday, October 23rd. UBS Group dropped their target price on Danaher from $309.00 to $305.00 and set a “buy” rating on the stock in a research report on Wednesday, October 23rd. KeyCorp lifted their price target on Danaher from $290.00 to $310.00 and gave the company an “overweight” rating in a research note on Wednesday, October 23rd. Finally, Robert W. Baird cut their price objective on Danaher from $278.00 to $277.00 and set an “outperform” rating for the company in a research report on Wednesday, October 23rd. Six research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $285.55.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.